Kristopher Amaro-Hosey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kristopher Amaro-Hosey has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Caridad Pontes
Universitat Autónoma de Barcelona
1 shared publication - Carlos Roncero
Department of Health Sciences, Miguel de Cervantes European University (UEMC), 47012 Valladolid, Spain
1 shared publication - Claudia Erika Delgado- Espinoza
Universitat Autonoma de Barcelona, Cerdanyola del Valles, Spain
1 shared publication - Cristina Sánchez-Mora
Department of Psychiatry, Hospital Universitari Vall d’Hebron, Barcelona, Spain
1 shared publication - Dolors Capellà
TransLab Research Group, Department of Medical Sciences, Faculty of Medicine, University of Girona, Girona, Spain
1 shared publication - Elena Ros-Cucurull
Addiction and Dual Diagnosis Unit, Vall Hebron University Hospital, Barcelona, Spain; Psychiatry Service, CIBERSAM, Vall Hebron University Hospital, Barcelona, Spain; Autonomous University of Barcelona, Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
- 17 December 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (5) , 1438-1444
Low‐intervention clinical trials in Spain: Do they progress?
Aims: Low‐Intervention Clinical Trials (LICTs) are generally pragmatic trials that investigate medicinal products already authorized for use. In 2014, simplified regulatory frameworks were introduced for LICTs with the aim of reducing regulatory burden and operational complexity, to foster non‐commercial clinical trials (NCCTs); the mandatory implementation of CTIS in 2023 may have impacted LICTs feasibility. Our aim was to describe the main characteristics of LICTs approved in Spain over a ten‐year period. Methods: Cross‐sectional descriptive analysis of LICTs registered between 2014 and 2023, in the Spanish Clinical Studies Registry (REec) database, mandatory to all authorized trials. Results: Between January 2014 and December 2023, 8497 clinical trials were registered in REec, of which only 3.8% (N = 322) were classified as LICTs. No drop in the overall proportion of LICTs was seen in 2023. Most LICTs were sponsored by non‐commercial entities and funded primarily through sponsors' own resources. LICTs were frequently monocentric phase IV studies evaluating commercialized medicinal products. The principal objectives of the trials included efficacy and/or safety, while pharmacoeconomics, pharmacogenetics, pharmacogenomics and bioequivalence were comparatively infrequent as main objectives. Most trial designs were randomized, but blinded trials were less frequent, and only a minority were placebo‐controlled. Conclusions: Despite their critical role in establishing effectiveness and safety of authorized medicinal products in pragmatic clinical settings, LICTs still constitute a relatively small proportion of all clinical trials approved in Spain, and their designs have area for improvement in terms of robustness. There was no apparent effect of CTIS implementation on LICTs activity.
- 17 December 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (5) , 1438-1444
Open AccessLow‐intervention clinical trials in Spain: Do they progress?
Aims: Low‐Intervention Clinical Trials (LICTs) are generally pragmatic trials that investigate medicinal products already authorized for use. In 2014, simplified regulatory frameworks were introduced for LICTs with the aim of reducing regulatory burden and operational complexity, to foster non‐commercial clinical trials (NCCTs); the mandatory implementation of CTIS in 2023 may have impacted LICTs feasibility. Our aim was to describe the main characteristics of LICTs approved in Spain over a ten‐year period. Methods: Cross‐sectional descriptive analysis of LICTs registered between 2014 and 2023, in the Spanish Clinical Studies Registry (REec) database, mandatory to all authorized trials. Results: Between January 2014 and December 2023, 8497 clinical trials were registered in REec, of which only 3.8% (N = 322) were classified as LICTs. No drop in the overall proportion of LICTs was seen in 2023. Most LICTs were sponsored by non‐commercial entities and funded primarily through sponsors' own resources. LICTs were frequently monocentric phase IV studies evaluating commercialized medicinal products. The principal objectives of the trials included efficacy and/or safety, while pharmacoeconomics, pharmacogenetics, pharmacogenomics and bioequivalence were comparatively infrequent as main objectives. Most trial designs were randomized, but blinded trials were less frequent, and only a minority were placebo‐controlled. Conclusions: Despite their critical role in establishing effectiveness and safety of authorized medicinal products in pragmatic clinical settings, LICTs still constitute a relatively small proportion of all clinical trials approved in Spain, and their designs have area for improvement in terms of robustness. There was no apparent effect of CTIS implementation on LICTs activity.
- Open Access
- 1 August 2023
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 18 (3) , 307-317
Drug-induced Sudden Death: A Scoping Review
Background: The risk of sudden cardiac death (SCD) can be increased with the use of drugs. However, it has been described heterogeneously in the literature. Objective: This study aims to systematically review epidemiological studies dealing with druginduced sudden death, describe their methodologies, and summarize the results found. Methods: A scoping review has been carried out using Medline electronic database. The search was limited up to 2020. Epidemiological studies were included, and case reports or case series were excluded. Results: Out of 3,114 potential articles, 74 were included. Most studies originated from North America (40.5%) or Europe (39.2%). Case-control (47.3%) or cohort (40.5%) studies were the most common designs. The data for outcomes and exposure were retrieved mainly from administrative databases (37.8%) or medical charts/hospital discharge reports (32.4%), but most studies used several sources of information. A composite variable of sudden death or SCD, mainly with ventricular arrhythmia, was the most frequently used endpoint. Only 18.9% of the studies included autopsy results to confirm the death. Psychotropic drugs were the most frequently studied. An increased risk of different outcomes for typical antipsychotics, tricyclic antidepressants, domperidone, and antiepileptics is suggested. Conclusion: The methodologies used were highly heterogeneous, and the results were, in general, not conclusive. An improvement of the methodologies is needed to achieve a conclusion regarding the risk of SCD associated with drug use.
- 1 August 2023
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 18 (3) , 307-317
Open AccessDrug-induced Sudden Death: A Scoping Review
Background: The risk of sudden cardiac death (SCD) can be increased with the use of drugs. However, it has been described heterogeneously in the literature. Objective: This study aims to systematically review epidemiological studies dealing with druginduced sudden death, describe their methodologies, and summarize the results found. Methods: A scoping review has been carried out using Medline electronic database. The search was limited up to 2020. Epidemiological studies were included, and case reports or case series were excluded. Results: Out of 3,114 potential articles, 74 were included. Most studies originated from North America (40.5%) or Europe (39.2%). Case-control (47.3%) or cohort (40.5%) studies were the most common designs. The data for outcomes and exposure were retrieved mainly from administrative databases (37.8%) or medical charts/hospital discharge reports (32.4%), but most studies used several sources of information. A composite variable of sudden death or SCD, mainly with ventricular arrhythmia, was the most frequently used endpoint. Only 18.9% of the studies included autopsy results to confirm the death. Psychotropic drugs were the most frequently studied. An increased risk of different outcomes for typical antipsychotics, tricyclic antidepressants, domperidone, and antiepileptics is suggested. Conclusion: The methodologies used were highly heterogeneous, and the results were, in general, not conclusive. An improvement of the methodologies is needed to achieve a conclusion regarding the risk of SCD associated with drug use.
- 17 March 2017
- Published by Walter de Gruyter GmbH in Reviews in the Neurosciences
- Vol. 28 (5) , 499-508
Peripheral levels of BDNF and opiate-use disorder: literature review and update
Several neurobiological factors are related to opiate-use disorder (OUD), and among them, neurotrophins have a relevant role. Brain-derived neurotrophic factor (BDNF) is a central neurotrophin involved in many neuronal processes, and it has been related to several psychiatric diseases and addictive disorders. BDNF can be measured in plasma and serum; its levels may reflect BDNF concentrations in the central nervous system (CNS) and, indirectly, CNS processes. Hence, peripheral BDNF could be a biomarker in clinical practice. This manuscript explores the findings about peripheral BDNF and OUD in humans. Opiates induce neurotoxicity in the CNS, which may be correlated with modifications in BDNF expression. Thus, basal levels of peripheral BDNF in OUD patients may be altered, which could be modified with abstinence. Also, opiates may modify epigenetic processes that may be associated with peripheral concentrations of BDNF, and in this line, withdrawal could reflect recovering processes in the CNS. Additionally, treatment modifies the peripheral concentrations of BDNF, but the clinical implications of those changes are yet not elucidated. No specific conclusion can be performed and more investigation in this area is necessary to elucidate the real potential of peripheral BDNF as a biomarker.
- 17 March 2017
- Published by Walter de Gruyter GmbH in Reviews in the Neurosciences
- Vol. 28 (5) , 499-508
Peripheral levels of BDNF and opiate-use disorder: literature review and update
Several neurobiological factors are related to opiate-use disorder (OUD), and among them, neurotrophins have a relevant role. Brain-derived neurotrophic factor (BDNF) is a central neurotrophin involved in many neuronal processes, and it has been related to several psychiatric diseases and addictive disorders. BDNF can be measured in plasma and serum; its levels may reflect BDNF concentrations in the central nervous system (CNS) and, indirectly, CNS processes. Hence, peripheral BDNF could be a biomarker in clinical practice. This manuscript explores the findings about peripheral BDNF and OUD in humans. Opiates induce neurotoxicity in the CNS, which may be correlated with modifications in BDNF expression. Thus, basal levels of peripheral BDNF in OUD patients may be altered, which could be modified with abstinence. Also, opiates may modify epigenetic processes that may be associated with peripheral concentrations of BDNF, and in this line, withdrawal could reflect recovering processes in the CNS. Additionally, treatment modifies the peripheral concentrations of BDNF, but the clinical implications of those changes are yet not elucidated. No specific conclusion can be performed and more investigation in this area is necessary to elucidate the real potential of peripheral BDNF as a biomarker.